Adaptimmune: Application for Treatment of Advanced Synovial Sarcoma with Priority Review OKd

 

• If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade

Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its Biologics License Application (BLA) for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma. The application has a Prescription Drug User Fee Act (PDUFA) target action date of August 4, 2024.

https://www.newsfilecorp.com/release/196074/Adaptimmune-Announces-U.S.-FDA-Acceptance-of-Biologics-License-Application-for-Afamicel-for-the-Treatment-of-Advanced-Synovial-Sarcoma-with-Priority-Review